文献速递其他结缔组织病

来氟米特联合羟氯喹治疗干燥综合征:RepurpSS-II随机对照2b期试验

Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial.
PubMed 文献 · Lancet Rheumatol · 2026-05-20

RepurpSS-II是一项在荷兰乌得勒支大学医学中心开展的随机、双盲、安慰剂对照2b期试验,纳入46例ESSDAI≥5的成人干燥综合征患者,比较来氟米特(20 mg)联合羟氯喹(400 mg)每日一次与安慰剂的疗效。

要点

  • 治疗组发生1例严重不良事件(心肌梗死),可能与研究药物无关。
  • 两组不良事件相似,胃肠道不适最常见。

核心结论

  • 来氟米特联合羟氯喹对系统活动性干燥综合征有效且总体耐受良好。

研究设计与样本

  • 随机、双盲、安慰剂对照2b期试验在荷兰乌得勒支大学医学中心开展。
  • 纳入46例18-75岁、ESSDAI≥5的成人干燥综合征患者,按1:1随机分配至来氟米特20 mg联合羟氯喹400 mg每日一次组(n=21)或安慰剂组(n=25)。
  • 主要终点为24周ESSDAI自基线变化的组间差异,采用意向性治疗人群混合效应分析。

主要发现

  • 治疗组发生1例严重不良事件(因心肌梗死住院),可能与研究药物无关。
  • 胃肠道不适最常见,治疗组6/21例(29%),安慰剂组4/25例(16%)。
  • 研究期间无死亡。

关键数值与推荐

  • 入选标准为成人18-75岁、ESSDAI≥5;排除2年内有妊娠意愿或近6个月内使用过来氟米特或羟氯喹者。
  • 主要终点为24周ESSDAI自基线变化的组间差异。

临床怎么用

  • 来氟米特联合羟氯喹可作为系统活动性干燥综合征的一种可负担且广泛可及的治疗选择。
  • 治疗期间需关注胃肠道不适等不良事件。

局限性

  • 样本量较小(共46例),研究于单一中心开展。
  • 未来需在其他人群(如系统疾病活动度低但患者报告结局高者)中验证疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sjögren's disease is a systemic autoimmune disease characterised by secretory gland dysfunction that lacks effective systemic treatment. We aimed to replicate the findings of the RepurpSS-I trial and determine the efficacy and safety of leflunomide and hydroxychloroquine combination therapy as a first conventional treatment for Sjögren's disease. METHODS: This randomised, placebo-controlled, double-blind, phase 2b trial (RepurpSS-II) was done at University Medical Center Utrecht, The Netherlands. Eligible patients were adults aged 18-75 years with an European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) of at least 5. Exclusion criteria included an active wish to conceive within 2 years or use of leflunomide or hydroxychloroquine in the past 6 months. Patients were randomly assigned (1:1) to receive placebo or leflunomide (20 mg) and hydroxychloroquine (400 mg) orally, once a day. Investigators, patients, and laboratory staff were masked to treatment until 24 weeks. The primary endpoint was the between-group difference in change in ESSDAI from baseline to 24 weeks. Primary and secondary analyses were done in the intention-to-treat population using mixed-effect analysis, accounting for repeated outcome assessment and controlling for baseline ESSDAI. This study was registered with the European Union Clinical Trials Register (EudraCT 2020-001933-11) and is completed. Patients from the RepurpSS-I trial and Sjögren's disease patient representatives contributed to the study design. FINDINGS: Between Oct 12, 2021, and July 5, 2024, 243 patients were approached for inclusion. 158 were excluded before screening and 39 were excluded following screening. 46 patients were enrolled and randomly assigned to receive leflunomide-hydroxychloroquine (n=21) or placebo (n=25). Median age was 55·00 years (IQR 51·00-60·50). 43 (93%) of 46 patients were female and three (7%) were male. The mean difference in ESSDAI between the leflunomide-hydroxychloroquine group and placebo group at 24 weeks was -4·135 (95% CI -6·558 to -1·709, p=0·0012). One serious adverse event occurred in the treatment group; probably unrelated to study medication (hospital admission for myocardial infarction). Adverse events were similar between groups; gastrointestinal discomfort was most common (six [29%] of 21 patients in the leflunomide-hydroxychloroquine group and four [16%] of 25 in the placebo group). There were no deaths during the study. INTERPRETATION: This study supports previous findings that leflunomide in combination with hydroxychloroquine is an effective treatment for systemically active Sjögren's disease and was generally well tolerated. This therapy might be an affordable and widely available option for patients with active systemic Sjögren's disease. Future studies should investigate whether this combination is effective in other patient populations, such as those with low systemic disease activity but high patient-reported outcomes. FUNDING: ZonMW and ReumaNederland.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Wong WY, Rijnenberg D, Baloche VMD, et al. Repurposing leflunomide and hydroxychloroquine to treat Sjögren's disease (RepurpSS-II): a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Rheumatol. 2026. PMID: 42161318. doi:10.1016/S2665-9913(26)00075-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。